plomestane plomestane plomestane (inn, usan; former developmental code name mdl-18962; also known as propargylestrenedione, ped) is a steroidal, irreversible aromatase inhibitor which was under development by marion merrell dow/hoechst marion russell (now hoechst ag) as an antineoplastic agent for the treatment of breast cancer. it was found to be effective in preclinical studies and was also found to produce few adverse effects in human clinical trials, significantly reducing estrogen levels with a single administration. however, development of the drug for clinical use was halted due to "technical issues" and it was never marketed. plomestaneclinical dataother namesmdl-18962; propargylestrenedione; ped; 10-(2-propyn-1-yl)estr-4-ene-3,17-dione; 10-propargylestr-4-ene-3,17-dioneatc codenoneidentifiers iupac name 10h-(2-propynyl)-estr-4-ene-3,17-dione cas number77016-85-4pubchem cid9904788chemspider8080442uniifl3vs913twchemical and physical dataformulac21h26o2molar mass310.437 g·mol−13d model (jsmol)interactive image smiles o=c4\c=c3/(cc#c)(2cc1(c(=o)cc12cc3)c)cc4 inchi inchi=1s/c21h26o2/c1-3-10-21-12-8-15(22)13-14(21)4-5-16-17-6-7-19(23)20(17,2)11-9-18(16)21/h1,13,16-18h,4-12h2,2h3/t16-,17-,18-,20-,21-/m0/s1key:jkpdeyaocsqbsz-oeujliazsa-n in addition to its activity as an aromatase inhibitor, plomestane has weak androgenic properties.